Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial
RH McAllister-Williams, IM Anderson… - The Lancet …, 2016 - thelancet.com
Background Many patients with major depressive disorder have treatment-resistant
depression, defined as no adequate response to two consecutive courses of
antidepressants. Some evidence suggests that antiglucocorticoid augmentation of
antidepressants might be efficacious in patients with major depressive disorder. We aimed
to test the proof of concept of metyrapone for the augmentation of serotonergic
antidepressants in the clinically relevant population of patients with treatment-resistant …
depression, defined as no adequate response to two consecutive courses of
antidepressants. Some evidence suggests that antiglucocorticoid augmentation of
antidepressants might be efficacious in patients with major depressive disorder. We aimed
to test the proof of concept of metyrapone for the augmentation of serotonergic
antidepressants in the clinically relevant population of patients with treatment-resistant …
以上显示的是最相近的搜索结果。 查看全部搜索结果